Stay updated on Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Sign up to get notified when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.

Latest updates to the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.3.4 updated in the page history (replacing v3.3.3).SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedA new revision entry (v3.3.3) was added to the record history for NCT04249362, and the HHS Vulnerability Disclosure link was removed from the footer.SummaryDifference0.1%

- Check50 days agoChange DetectedNew Revision: v3.3.2 appears in the history, replacing v3.3.1; this reflects a site update with no changes to trial data or history content.SummaryDifference0.1%

- Check57 days agoChange DetectedThe only change is the addition of a site revision label 'Revision: v3.3.1' and the removal of 'Revision: v3.2.0'. There are no changes to study records, statuses, or patient-facing content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedRemoved a general government funding/operating status notice that was displayed at the top of the page; the rest of the trial record content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check78 days agoChange DetectedThe old and new screenshots display the same Version History and study status sections with no substantive updates; changes are limited to formatting and layout.SummaryDifference0.1%

Stay in the know with updates to Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.